WallStreetZenWallStreetZen

NASDAQ: ENLV
Enlivex Therapeutics Ltd Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ENLV

Based on 2 analysts offering 12 month price targets for Enlivex Therapeutics Ltd

Min Forecast
$7.00+629.17%
Avg Forecast
$10.00+941.67%
Max Forecast
$13.00+1,254.17%

Should I buy or sell ENLV stock?

Based on 2 analysts offering ratings for Enlivex Therapeutics Ltd.

Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ENLV stock forecasts and price targets.

ENLV stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-10-29
lockedlocked$00.00+00.00%2025-09-02

1 of 1

Forecast return on equity

Is ENLV forecast to generate an efficient return?

Company
-133.24%
Industry
255.07%
Market
226.45%
ENLV's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ENLV forecast to generate an efficient return on assets?

Company
-111.24%
Industry
91.01%
ENLV is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ENLV earnings per share forecast

What is ENLV's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$0.53
Avg 2 year Forecast
-$0.59
Avg 3 year Forecast
-$0.80

ENLV revenue forecast

What is ENLV's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

ENLV vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ENLV$0.96$10.00+941.67%Strong Buy
QCLS$5.57N/AN/A
CVKD$11.11N/AN/A
NNVC$1.32N/AN/A
NEUP$4.21$21.00+398.81%Strong Buy
View Top Biotech Stocks

Enlivex Therapeutics Stock Forecast FAQ

Is Enlivex Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: ENLV) stock is to Strong Buy ENLV stock.

Out of 2 analysts, 1 (50%) are recommending ENLV as a Strong Buy, 1 (50%) are recommending ENLV as a Buy, 0 (0%) are recommending ENLV as a Hold, 0 (0%) are recommending ENLV as a Sell, and 0 (0%) are recommending ENLV as a Strong Sell.

If you're new to stock investing, here's how to buy Enlivex Therapeutics stock.

What is ENLV's earnings growth forecast for 2025-2027?

(NASDAQ: ENLV) Enlivex Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 44.08%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.53%.

Enlivex Therapeutics's earnings in 2025 is -$12,701,000.On average, 4 Wall Street analysts forecast ENLV's earnings for 2025 to be -$12,761,025, with the lowest ENLV earnings forecast at -$13,808,046, and the highest ENLV earnings forecast at -$11,478,364. On average, 4 Wall Street analysts forecast ENLV's earnings for 2026 to be -$14,371,640, with the lowest ENLV earnings forecast at -$14,046,116, and the highest ENLV earnings forecast at -$14,539,261.

In 2027, ENLV is forecast to generate -$19,327,378 in earnings, with the lowest earnings forecast at -$18,569,442 and the highest earnings forecast at -$19,895,830.

What is ENLV's revenue growth forecast for 2025-2027?

(NASDAQ: ENLV) Enlivex Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.3%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.86%.

Enlivex Therapeutics's revenue in 2025 is $0.On average, 4 Wall Street analysts forecast ENLV's revenue for 2025 to be $0, with the lowest ENLV revenue forecast at $0, and the highest ENLV revenue forecast at $0. On average, 4 Wall Street analysts forecast ENLV's revenue for 2026 to be $0, with the lowest ENLV revenue forecast at $0, and the highest ENLV revenue forecast at $0.

In 2027, ENLV is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is ENLV's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: ENLV) forecast ROA is -111.24%, which is lower than the forecast US Biotechnology industry average of 91.01%.

What is ENLV's Price Target?

According to 2 Wall Street analysts that have issued a 1 year ENLV price target, the average ENLV price target is $10.00, with the highest ENLV stock price forecast at $13.00 and the lowest ENLV stock price forecast at $7.00.

On average, Wall Street analysts predict that Enlivex Therapeutics's share price could reach $10.00 by Oct 29, 2026. The average Enlivex Therapeutics stock price prediction forecasts a potential upside of 941.67% from the current ENLV share price of $0.96.

What is ENLV's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: ENLV) Enlivex Therapeutics's current Earnings Per Share (EPS) is -$0.55. On average, analysts forecast that ENLV's EPS will be -$0.53 for 2025, with the lowest EPS forecast at -$0.57, and the highest EPS forecast at -$0.47. On average, analysts forecast that ENLV's EPS will be -$0.59 for 2026, with the lowest EPS forecast at -$0.58, and the highest EPS forecast at -$0.60. In 2027, ENLV's EPS is forecast to hit -$0.80 (min: -$0.76, max: -$0.82).

What is ENLV's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: ENLV) forecast ROE is -133.24%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.